Need Help?

Mechanism and targeted therapy of Vemurafenib-Resistant Hairy-Cell Leukemia

The discovery of the BRAF V600E mutation in almost all cases of hairy-cell leukemia has led to the widespread adoption of the BRAF inhibitor vemurafenib for treatment of chemotherapy-resistant cases. Impressive responses are reported; however, acquired resistance is common. Whilst diverse mechanisms of vemurafenib resistance have been elucidated in melanoma, the basis of resistance in HCL is unclear. Here we apply whole genome and deep targeted sequencing to investigate resistance mechanisms and potential therapeutic strategies in a patient with aquired resistance to vemurafenib.

Request Access

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS00001002366 Cancer Genomics

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Located in
EGAF00001839894 cram 19.8 GB
EGAF00001839895 cram 19.9 GB
EGAF00001839896 cram 18.8 GB
EGAF00001839897 cram 18.8 GB
EGAF00001839898 cram 17.5 GB
EGAF00001839899 cram 17.3 GB
EGAF00001839900 cram 37.7 GB
7 Files (149.7 GB)